RCS - Hutchmed China Ltd - Clinical Data to be Presented at ASH and ESMO Asia

HUTCHMED (China)Announcement

06/11/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241106:nRSF1476La&default-theme=true

RNS Number : 1476L  Hutchmed (China) Limited  06 November 2024

Press Release

 

HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress

 

Hong Kong, Shanghai & Florham Park, NJ - Wednesday, November 6, 2024:
HUTCHMED (China) Limited ("HUTCHMED (https://www.hutch-med.com/) ")
(Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from the
sovleplenib ESLIM-01 Phase III trial, as well as several
investigator-initiated studies of compounds discovered by HUTCHMED will be
presented at the American Society of Hematology ("ASH") Annual Meeting taking
place on December 7-10, 2024 in San Diego, USA, and the European Society for
Medical Oncology ("ESMO") Asia Congress 2024, taking place on December 6-8,
2024 in Singapore.

 

Long-term safety and efficacy data from a follow-on, open-label sub-study of
the extension stage of ESLIM-01 Phase III study of sovleplenib in adult
patients with chronic primary immune thrombocytopenia ("ITP") in China will be
reported at the 2024 ASH Annual Meeting (NCT05029635
(https://clinicaltrials.gov/study/NCT05029635) ). At data cut-off on January
31, 2024, a total of 179 patients were treated with at least one dose of
sovleplenib. 55.3% (99/179) of the patients were still on the treatment in the
sub-study, with a median duration of exposure of 56.6 weeks.

 

The follow-on sub-study data demonstrated that long-term treatment with
sovleplenib was effective in increasing and maintaining platelet count in
adults with chronic primary ITP in China. In the overall population, the
overall response was achieved by 81% (145/179) of the patients, with a durable
response rate of 51.4% and long-term durable response rate of 59.8%. The
median cumulative duration of platelet count ≥50×10⁹/L was 38.9 weeks.
The long-term treatment was well tolerated, with a safety profile consistent
with previous studies and no new safety signals were identified.

 

 Abstract title                                                                   Presenter / Lead author                                                          Presentation details
 2024 ASH ANNUAL MEETING - SPONSORED STUDY
 Long-Term Sovleplenib Treatment of Adults with Primary Immune Thrombocytopenia   Yu Hu                                                                            #2558 (https://ash.confex.com/ash/2024/webprogram/Paper204447.html)
 in China
Union Hospital, Tongji Medical College, Huazhong University of Science and

                                                                                  Technology, Wuhan, China                                                         Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster
                                                                                                                                                                   II

                                                                                                                                                                   Sunday, December 8, 2024

6:00 PM - 8:00 PM Pacific Time

 ESMO ASIA CONGRESS 2024 - INVESTIGATOR-INITIATED STUDIES
 Efficacy and safety of fruquintinib combined with serplulimab as 1st line        Wei Xue, Jiwei Huang                                                             # (https://cattendee.abstractsonline.com/meeting/20598/Session/79) 274MO
 treatment in advanced non-clear cell renal cell carcinoma (nccRCC): A

 single-arm, multicentre clinical trial                                           Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,   Mini Oral session: Genitourinary tumours
                                                                                  Shanghai, China

                                                                                                                                                                   Sunday, December 8, 2024

9:42 - 9:47 AM Singapore Time
 Stereotactic body radiation therapy followed by fruquintinib in combination      Chen Zhang, Yi Wang                                                              # (https://cattendee.abstractsonline.com/meeting/20598/Session/79) 81P
 with immunotherapy as third- and later-line treatment in metastatic colorectal

 cancer                                                                           Ningbo No.2 Hospital, Ningbo, China                                              Poster Display: Gastrointestinal tumours, colorectal

                                                                                                                                                                   Saturday, December 7, 2024
 Results from FRONT study: A multicenter, randomized, open-label clinical trial   Tianshu Liu, Xiaojing Xu                                                         # (https://cattendee.abstractsonline.com/meeting/20598/Session/79) 82P
 of fruquintinib as maintenance therapy after 1L treatment in metastatic

 colorectal cancer (mCRC)                                                         Zhongshan Hospital Affiliated to Fudan University, Shanghai, China               Poster Display: Gastrointestinal tumours, colorectal

                                                                                                                                                                   Saturday, December 7, 2024
 Fruquintinib in combination with S-1 for ESCC patients after first-line          Lin Zhao, Ningning Li                                                            # (https://cattendee.abstractsonline.com/meeting/20598/Session/79) 194P
 immunotherapy failure: Update of dose-finding results

                                                                                  Peking Union Medical College Hospital, Beijing, China                            Poster Display: Gastrointestinal tumours, colorectal

                                                                                                                                                                   Saturday, December 7, 2024
 Efficacy and safety of concurrent bevacizumab in combination with standard       Rongjie Tao, Hui Zhang                                                           # (https://cattendee.abstractsonline.com/meeting/20598/Session/79) 766P
 radiotherapy and temozolomide followed by bevacizumab in combination with

 temozolomide and surufatinib in glioblastoma: A phase 2 clinical trial           Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China         Poster Display: General interest

                                                                                                                                                                   Saturday, December 7, 2024

 

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage,
biopharmaceutical company. It is committed to the discovery, global
development and commercialization of targeted therapies and immunotherapies
for the treatment of cancer and immunological diseases. It has approximately
5,000 personnel across all its companies, at the center of which is a team of
about 1,800 in oncology/immunology. Since inception, HUTCHMED has focused on
bringing cancer drug candidates from in-house discovery to patients around the
world, with its first three medicines marketed in China, the first of which is
also approved in the US, Europe and Japan. For more information, please visit:
www.hutch-med.com (http://www.hutch-med.com/) or follow us on LinkedIn
(https://www.linkedin.com/company/hutchmed/) .

 

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the U.S. Private Securities Litigation Reform
Act of 1995. These forward-looking statements reflect HUTCHMED's current
expectations regarding future events, including but not limited to its
expectations regarding the therapeutic potential of fruquintinib, savolitinib,
sovleplenib and surufatinib, the further clinical development for
fruquintinib, savolitinib, sovleplenib and surufatinib, its expectations as to
whether any studies on fruquintinib, savolitinib, sovleplenib and surufatinib,
would meet their primary or secondary endpoints, and its expectations as to
the timing of the completion and the release of results from such studies.
Such risks and uncertainties include, among other things, assumptions
regarding enrollment rates and the timing and availability of subjects meeting
a study's inclusion and exclusion criteria; changes to clinical protocols or
regulatory requirements; unexpected adverse events or safety issues; the
ability of fruquintinib, savolitinib, sovleplenib and surufatinib, including
as combination therapies, to meet the primary or secondary endpoint of a
study, to obtain regulatory approval in different jurisdictions and to gain
commercial acceptance after obtaining regulatory approval; the potential
markets of fruquintinib, savolitinib, sovleplenib and surufatinib for a
targeted indication, and the sufficiency of funding. In addition, as certain
studies rely on the use of serplulimab, sintilimab, S-1, temozolomide and
bevacizumab as combination therapeutics, such risks and uncertainties include
assumptions regarding their safety, efficacy, supply and continued regulatory
approval. Existing and prospective investors are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
hereof. For further discussion of these and other risks, see HUTCHMED's
filings with the U.S. Securities and Exchange Commission, The Stock Exchange
of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update
or revise the information contained in this press release, whether as a result
of new information, future events or circumstances or otherwise.

Medical Information

This press release contains information about products that may not be
available in all countries, or may be available under different trademarks,
for different indications, in different dosages, or in different strengths.
Nothing contained herein should be considered a solicitation, promotion or
advertisement for any prescription drugs including the ones under development.

 

CONTACTS
 Investor Enquiries                       +852 2121 8200 / ir@hutch-med.com (mailto:ir@hutch-med.com)

 Media Enquiries
 Ben Atwell / Alex Shaw, FTI Consulting   +44 20 3727 1030 / +44 7771 913 902 (Mobile) /
                                          +44 7779 545 055 (Mobile) / HUTCHMED@fticonsulting.com
                                          (mailto:HUTCHMED@fticonsulting.com)
 Zhou Yi, Brunswick                       +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
                                          (mailto:HUTCHMED@brunswickgroup.com)

 Nominated Advisor
 Atholl Tweedie / Freddy Crossley /       +44 (20) 7886 2500

 Rupert Dearden, Panmure Liberum

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUPGCPGUPCUQQ